The FDA declined to review an application for a new mRNA flu vaccine. The decision highlights ongoing regulatory scrutiny around novel vaccine platforms.
February 12, 2026
The FDA declined to review an application for a new mRNA flu vaccine. The decision highlights ongoing regulatory scrutiny around novel vaccine platforms.